Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma

Immunology Letters

Volumn 169, Issue , 2016, Pages 23-32

  Ben Haj Ayed, Ahlem ^a,b   Moussa, Adnène ^a,c   Ghedira, Randa ^a,b   Gabbouj, Sallouha ^a   Miled, Souad ^c   Bouzid, Nadia ^a,d   Tebra Mrad, Sameh ^a,d   Bouaouina, Noureddine ^a,d   Chouchane, Lotfi ^a,e   Zakhama, Abdelfattah ^a,c   Hassen, Elham ^a,f  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b UNIVERSITY OF CARTHAGE   (Tunisia)

^c Fattouma Bourguiba University Hospital   (Tunisia)

^d FARHAT HACHED HOSPITAL   (Tunisia)

^e WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^f UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

Indoleamine 2,3 dioxygenase; Nasopharyngeal carcinoma; Survivals; T cell infiltration

Indexed keywords

CD3 ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; KI 67 ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CELL DENSITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TISSUE DISTRIBUTION; ADOLESCENT; AGED; CANCER STAGING; CHILD; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PREDICTIVE VALUE; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CHILD; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; YOUNG ADULT;

EID: 84947967487     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.11.012     Document Type: Article

References (54)

1. M.P. Curado, B. Edwards, H.R. Shin, J. Ferlay, M. Heanue, P. Boyle, et al. Cancer Incidence in Five Continents. Vol. IX IARC Scientific Publication, No 160 IARC Lyon (2007).
2. Boussen H., Ghorbal L., Naouel L., Bouaouina N., Gritli S., Benna F., et al. Nasopharyngeal cancer (NPC) around the Mediterranean area: standard of care. Crit. Rev. Oncol. Hematol. 2012, 84(Suppl. 1):e106-e109.
3. Chang Y., Tyan Y., Liu S., Tsai M., Pao C. Detection of Epstein-Barr virus DNA sequences in nasopharyngeal carcinoma cells by enzymatic DNA amplification. J. Clin. Microbiol. 1990, 28:2398-2402.
4. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin. Cancer Biol. 2002, 12:431-441.
5. Shanmugaratnam K., Chan S.H., de-Thé G., Goh J.E., Khor T.H., Simons M.J., et al. Histopathology of nasopharyngeal carcinoma. Cancer 1979, 44:1029-1044.
6. Li J., Zeng X., Mo H., Rolén U., Gao Y., Zhang X., et al. Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLoS One 2007, 2:e1122.
7. Lin X., Gudgeon N.H., Hui E.P., Jia H., Qun X., Taylor G.S., et al. CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients. Cancer Immunol. Immunother. 2008, 57:963-975.
8. Munn D.H., Zhou M., Attwood J., Bondarev I., Conway S., Marshall B., et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281:1191-1193.
9. Fallarino F., Grohmann U., Vacca C., Bianchi R., Orabona C., Spreca A., et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002, 9:1069-1077.
10. Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U., Ferrara G.B. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 2002, 196:459-468.
11. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9:1269-1274.
12. Astigiano S., Morandi B., Costa R., Mastracci L., D'Agostino A., Ratto G.B., et al. Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non small cell lung cancer. Neoplasia 2005, 7:390-396.
13. Choe J.Y., Yun J.Y., Jeon Y.K., Kim S.H., Park G., Huh J.R., et al. Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study. BMC Cancer 2014, 14:335.
14. Ye J., Liu H., Hu Y., Li P., Zhang G., Li Y. Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma. Virchows Arch. 2013, 462:73-81.
15. Zhang G., Liu W.L., Zhang L., Wang J.Y., Kuang M.H., Liu P., et al. Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma. Clin. Dev. Immunol. 2011, 2011. 384726.
16. Liu J., Lu G., Tang F., Liu Y., Cui G. Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas. Virchows Arch. 2009, 455:441-448.
17. Milano F., Jorritsma T., Rygiel A.M., Bergman J.J., Sondermeijer C., Ten Brinke A., et al. Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment. Scand. J. Immunol. 2008, 68:616-623.
18. O'Sullivan B., Yu E. Staging of nasopharyngeal carcinoma. Nasopharyngeal Cancer Medical Radiology 2010, 309-322. Springer, Berlin, Heidelberg. J.J. Lu, J.S. Cooper, A.W.M. Lee (Eds.).
19. Weinlich G., Murr C., Richardsen L., Winkler C., Fuchs D. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 2007, 214:8-14.
20. Suzuki Y., Suda T., Furuhashi K., Suzuki M., Fujie M., Hahimoto D., et al. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 2010, 67:361-365.
21. De Jong R.A., Nijman H.W., Boezen H.M., Volmer M., Ten Hoor K.A., Krijnen J., et al. Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer. Int. J. Gynecol. Cancer 2011, 21:1320-1327.
22. Lyon D.E., Walter J.M., Starkweather A.R., Schubert C.M., McCain N.L. Tryptophan degradation in women with breast cancer: a pilot study. BMC Res. Notes 2011, 4:156.
23. Cavia-Saiz M., Muñiz Rodríguez P., Llorente Ayala B., García-González M., Coma-Del Corral M.J., García Girón C. The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer. Mol. Biol. Rep. 2014, 41:2275-2279.
24. Yoshikawa T., Hara T., Tsurumi H., Goto N., Hoshi M., Kitagawa J., et al. Serum concentration of l-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur. J. Haematol. 2010, 84:304-309.
25. Creelan B.C., Antonia S., Bepler G., Garrett T.J., Simon G.R., Soliman H.H. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in stage III non-small cell lung cancer. Oncoimmunology 2013, 2:e23428.
26. Opitz C.A., Litzenburger U.M., Sahm F., Ott M., Tritschler I., Trump S., et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011, 478:197-203.
27. Mezrich J.D., Fechner J.H., Zhang X., Johnson B.P., Burlingham W.J., Bradfield C.A. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 2010, 185:3190-3198.
28. Nguyen N.T., Kimura A., Nakahama T., Chinen I., Masuda K., Nohara K., et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:19961-19966.
29. Smith C., Chang M.Y., Parker K.H., Beury D.W., DuHadaway J.B., Flick H.E., et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2012, 2:722-735.
30. Tanizaki Y., Kobayashi A., Toujima S., Shiro M., Mizoguchi M., Mabuchi Y., et al. Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment. Cancer Sci. 2014, 105:966-973.
31. Liu P., Xie B.L., Cai S.H., He Y.W., Zhang G., Yi Y.M., et al. Expression of indoleamine 2,3-dioxygenase in nasopharyngeal carcinoma impairs the cytolytic function of peripheral blood lymphocytes. BMC Cancer 2009, 9:416.
32. Liu W.L., Lin Y.H., Xiao H., Xing S., Chen H., Chi P.D., et al. Epstein-Barr virus infection induces indoleamine 2,3-dioxygenase expression in human monocyte-derived macrophages through p38/MAPK and NF-kappaB pathways: impairment in T cell functions. J. Virol. 2014, 88:6660-6671.
33. Riesenberg R., Weiler C., Spring O., Eder M., Buchner A., Popp T., et al. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin. Cancer Res. 2007, 13:6993-7002.
34. Ishio T., Goto S., Tahara K., Tone S., Kawano K., Kitano S. Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2004, 19:319-326.
35. Giannini A., Bianchi S., Messerini L., Gallo O., Gallina E., Asprella Libonati G., et al. Prognostic significance of accessory cells and lymphocytes in nasopharyngeal carcinoma. Pathol. Res. Pract. 1991, 187:496-502.
36. Taylor M.W., Feng G.S. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991, 5:2516-2522.
37. Babcock T.A., Carlin J.M. Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells. Cytokine 2000, 12:588-594.
38. Fujigaki S., Saito K., Sekikawa K., Tone S., Takikawa O., Fujii H., et al. Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur. J. Immunol. 2001, 31:2313-2318.
39. Liebau C., Baltzer A.W., Schmidt S., Roesel C., Karreman C., Prisack J.B., et al. Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. Anticancer Res. 2002, 22:931-936.
40. Hu H., Tang K.F., Chua Y.N., Lu J., Feng P., Chew C.T., et al. Expression of interleukin-18 by nasopharyngeal carcinoma cells: a factor that possibly initiates the massive leukocyte infiltration. Hum. Pathol. 2004, 35:722-728.
41. Huang Y.T., Sheen T.S., Chen C.L., Lu J., Chang Y., Chen J.Y., et al. Profile of cytokine expression in nasopharyngeal carcinomas: a distinct expression of interleukin 1 in tumor and CD4+ T cells. Cancer Res. 1999, 59:1599-1605.
42. Dukers D.F., Meij P., Vervoort M.B., Vos W., Scheper R.J., Meijer C.J., et al. Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J. Immunol. 2000, 165:663-670.
43. Hsu D.H., De Waal Malefyt R., Fiorentino D.F., Dang M.N., Vieira P., de Vries J., Spits, et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science 1990, 250:830-832.
44. Song H., Park H., Kim J., Park G., Kim Y.S., Kim S.M., et al. IDO metabolite produced by EBV-transformed B cells inhibits surface expression of NKG2D in NK cells via the c-Jun N-terminal kinase (JNK) pathway. Immunol. Lett. 2011, 136:187-193.
45. Brandacher G., Perathoner A., Ladurner R., Schneeberger S., Obrist P., Winkler C., et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 2006, 12:1144-1151.
46. Ino K., Yamamoto E., Shibata K., Kajiyama H., Yoshida N., Terauchi M., Nawa A., et al. Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin. Cancer Res. 2008, 14:2310-2317.
47. Ino K., Yoshida N., Kajiyama H., Shibata K., Yamamoto E., Kidokoro K., et al. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br. J. Cancer 2006, 95:1555-1561.
48. Engin A.B., Ozkan Y., Fuchs D., Yardim-Akaydin S. Increased tryptophan degradation in patients with bronchus carcinoma. Eur. J. Cancer Care (Engl.) 2010, 19:803-808.
49. Inaba T., Ino K., Kajiyama H., Shibata K., Yamamoto E., Kondo S., et al. Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy. Gynecol. Oncol. 2010, 117:423-428.
50. Jalbout M., Bel Hadj Jrad B., Bouaouina N., Gargouri J., Yacoub S., Zakhama A., et al. Autoantibodies to tubulin are specifically associated with the young age onset of the nasopharyngeal carcinoma. Int. J. Cancer 2002, 101:146-150.
51. Karray H., Ayadi W., Fki L., Hammami A., Daoud J., Drira M.M., et al. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia. J. Med. Virol. 2005, 75:593-602.
52. Khabir A., Ghorbel A., Daoud J., Frikha M., Drira M.M., Laplanche A., et al. Similar BCL-X but different BCL-2 levels in the two age groups of north African nasopharyngeal carcinomas. Cancer Detect. Prev. 2003, 27:250-255.
53. Khabir A., Sellami A., Sakka M., Ghorbel A., Daoud J., Frikha M., et al. Contrasted frequencies of p53 accumulation in the two age groups of North African nasopharyngeal carcinomas. Clin. Cancer Res. 2000, 6:3932-3936.
54. Allaya N., Khabir A., Sallemi-Boudawara T., Sellami N., Daoud J., Ghorbel A., et al. Over-expression of miR-10b in NPC patients: correlation with LMP1 and Twist1. Tumor Biol. 2015, 36:3807-3814.